saline placebo (f23f77)

Saline placebo, specifically bacteriostatic saline in this context, is a pharmacologically inactive solution used as a control arm in clinical research. In the Phase II trial (NCT02709304) conducted by the University of Colorado, Denver, this saline placebo was administered to young adult participants with Down syndrome to serve as a comparator for sargramostim (recombinant human GM-CSF). The study was designed to evaluate the safety and efficacy of sargramostim, using the saline injections to establish a baseline for safety observations and to control for the placebo effect. As a placebo, it lacks the active biologic agent and is intended to have no therapeutic effect on the underlying condition, allowing researchers to isolate the specific biological impact of the experimental treatment.

Other names

bacteriostatic salineplacebo